高级检索
当前位置: 首页 > 详情页

Comparison of salvage chemoradiation versus salvage surgery for recurrent esophageal squamous cell carcinoma after definitive radiochemotherapy or radiotherapy alone

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [1]Division of Thoracic Oncology, West China Hospital, West China School of Clinical Medicine, Sichuan University [2]Departments of Pathology, Sichuan Tumor Hospital, Chengdu [3]Division of Radiation Oncology, Sichuan Tumor Hospital, Chengdu [4]Division of Radiation Oncology, Zhengzhou University Affiliated Tumor Hospital, Henan Tumor Hospital, [5]Division of Thoracic Oncology, Zhongshan University Affiliated Tumor Hospital, Zhengzhou [6]Departments of Pathology, Anyang Tumor Hospital, Anyang [7]Department of Medical Oncology, Kaifeng Tumor Hospital, Kaifeng, China
出处:
ISSN:

关键词: esophageal cancer prognosis recurrence salvage therapy squamous cell carcinoma

摘要:
A consensus treatment strategy for esophageal squamous cell carcinoma (ESCC) patients who recur after definitive radiochemotherapy/radiotherapy has not been established. This study compared the outcomes in ESCC patients who underwent salvage surgery, salvage chemoradiation (CRT) or best supportive care (BSC) for local recurrence. Ninety-five patients with clinical stage I to III ESCC who had completely responded to the initial definitive radiochemotherapy or radiotherapy alone and developed local recurrence were enrolled in this study. Fifty-one of them received salvage esophagectomy, and R0 resection was performed in 41 patients, 36 underwent salvage CRT, and the remaining eight patients received BSC only. The 5-year overall survival was 4.6% for the 87 patients receiving salvage surgery or CRT, while all patients in the BSC group died within 12.0 months, the difference was statistically significant (P = 0.018). The 1-, 3-, 5-year survival rates in the salvage surgery and salvage CRT groups were 45.1%, 20.0%, 6.9% and 51.7%, 12.2%, 3.1%, respectively, there was no difference of overall survival between the two groups (P = 0.697). Patients also presented with lymph node relapse had inferior survival compared to those with isolated local tumor recurrence after salvage therapy. In the salvage surgery group, infections occurred in eight patients, and three developed anastomotic leakage. In the salvage CRT group, grade 2-4 esophagitis and radiation pneumonitis was observed in 19 and 3 patients, respectively. Seven patients (19.4%) developed esophagotracheal fistula or esophageal perforation. This study of salvage CRT versus salvage surgery for recurrent ESCC after definitive radiochemotherapy or radiotherapy alone did not demonstrate a statistically significant survival difference, but the frequency of complications including esophagotracheal fistula and esophageal perforation following salvage CRT was high.

语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2014]版:
大类 | 4 区 医学
小类 | 4 区 胃肠肝病学
最新[2023]版:
大类 | 3 区 医学
小类 | 4 区 胃肠肝病学
JCR分区:
出版当年[2014]版:
Q4 GASTROENTEROLOGY & HEPATOLOGY
最新[2023]版:
Q3 GASTROENTEROLOGY & HEPATOLOGY

影响因子: 最新[2023版] 最新五年平均 出版当年[2014版] 出版当年五年平均 出版前一年[2013版] 出版后一年[2015版]

第一作者:
第一作者机构: [1]Division of Thoracic Oncology, West China Hospital, West China School of Clinical Medicine, Sichuan University [4]Division of Radiation Oncology, Zhengzhou University Affiliated Tumor Hospital, Henan Tumor Hospital, [*2]Division of Radiation Oncology, Zhengzhou University Affiliated Tumor Hospital, Henan Tumor Hospital, Zhengzhou University, 127, Dongming Road, Zhengzhou 450008, China.
通讯作者:
通讯机构: [1]Division of Thoracic Oncology, West China Hospital, West China School of Clinical Medicine, Sichuan University [4]Division of Radiation Oncology, Zhengzhou University Affiliated Tumor Hospital, Henan Tumor Hospital, [*1]West China Hospital, Cancer Center, West China School of Medicine, Sichuan University, 37, Guoxue Lane, Chengdu 610041, China [*2]Division of Radiation Oncology, Zhengzhou University Affiliated Tumor Hospital, Henan Tumor Hospital, Zhengzhou University, 127, Dongming Road, Zhengzhou 450008, China.
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:53080 今日访问量:0 总访问量:4588 更新日期:2025-01-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持:重庆聚合科技有限公司 地址:成都市人民南路四段55号